IGF-1 LR3 Complete Research Profile: A Research-Use-Only Science Guide to the Long R3 Analog

IGF-1 LR3 is a research-grade reference protein supplied strictly for in-vitro and laboratory research use only. It is not for human or animal consumption, is not FDA approved for any use represented here, and is not a drug, supplement, cosmetic, or treatment for any growth, metabolic, or muscular condition. This page is third-person science education about what researchers investigate when they study IGF-1 LR3 in cell cultures and animal models. It does not describe or endorse taking, dosing, or administering any substance, and any health question belongs with a licensed clinician.

What IGF-1 LR3 Is

IGF-1 LR3 is an engineered analog of insulin-like growth factor 1, a naturally occurring 70-residue protein that acts as a principal mediator of growth hormone signaling in mammals. The analog carries two deliberate departures from the native sequence. A thirteen-residue extension is added at the amino terminus, which is the source of the word Long in the name, and the glutamic acid at position 3 is replaced with arginine, which is the source of R3. The resulting molecule is 83 residues rather than 70.

On this page IGF-1 LR3 is treated entirely as laboratory science. The material supplied by Peptides Factory Direct is a reference compound for controlled research, never a product for personal use. It is worth stating plainly that this compound is one of the most misrepresented materials in the research category, and nothing here should be read as describing an effect in a person. What is documented about it comes from receptor pharmacology, cell-culture systems, and animal studies. For the underlying biology of how signaling proteins work, see the primer on what peptides are, and for the wider family of compounds touching this axis see the growth hormone peptides category.

• Class: engineered analog of insulin-like growth factor 1, 83 residues, produced recombinantly.
• Modifications: thirteen-residue N-terminal extension plus a glutamate-to-arginine substitution at position 3.
• Research status: reference material for in-vitro and animal study only, never a medicine, supplement, or cosmetic.
• Primary research interest: IGF-1 receptor signaling studied without confounding from binding proteins.
• Catalog listing and specifications: IGF-1 LR3.

Structure: Two Modifications With One Purpose

Both engineered changes exist to solve the same experimental problem. Native insulin-like growth factor 1 does not circulate freely. It is bound almost entirely by a family of six insulin-like growth factor binding proteins, designated IGFBP-1 through IGFBP-6, which hold the growth factor in complexes and regulate how much is available to engage its receptor at any moment. That binding is a real feature of the biology, not an artifact, and in an intact organism it is a central layer of control.

For a researcher trying to characterize what the receptor itself does, however, binding proteins are a confound. If the amount of free growth factor in a culture medium varies with binding protein expression, and binding protein expression varies with cell type and culture condition, then a dose-response curve measures a mixture of receptor pharmacology and binding protein sequestration rather than receptor pharmacology alone. The arginine substitution at position 3 sharply reduces affinity for the binding proteins, and the amino-terminal extension further alters the interaction, which together yield a molecule that engages the receptor with far less of the sequestration variable in the way.

That is the entire design rationale, and it is worth being precise about what it means. The modifications do not make the analog a more powerful version of the native protein in any biological sense. They make it a cleaner instrument for asking a narrow question in a controlled system, at the cost of removing a regulatory layer that exists in living organisms for good reason. A tool built by deleting a control mechanism is useful in a dish and correspondingly less representative of intact physiology.

The IGF-1 Receptor and Its Signaling Cascades

The IGF-1 receptor is a transmembrane receptor tyrosine kinase, structurally related to the insulin receptor and assembled as a disulfide-linked heterotetramer of two alpha and two beta subunits. Ligand binding to the extracellular alpha subunits produces a conformational change that activates the intracellular kinase domains of the beta subunits, which then autophosphorylate on tyrosine residues and create docking sites for adaptor proteins.

Two downstream cascades dominate the literature. The PI3K-Akt pathway proceeds through insulin receptor substrate proteins to phosphoinositide 3-kinase and then Akt, and it is studied for endpoints associated with protein synthesis, metabolic regulation, and cell survival, frequently through the mTOR node further downstream. The MAPK-ERK pathway proceeds through Grb2 and Ras and is studied more for proliferation and differentiation endpoints. Which cascade dominates in a given experiment depends on cell type, receptor density, and stimulus duration, which is why researchers routinely measure phosphorylation of multiple nodes rather than assuming one pathway.

Receptor cross-reactivity is a recurring methodological theme. Because the IGF-1 receptor and the insulin receptor are structurally similar and can form hybrid receptors containing subunits of both, an experiment that stimulates one system may produce signaling through the other. Researchers control for this with receptor-selective antagonists, knockdown of one receptor, or measurement in cells with characterized receptor expression profiles. Ignoring the overlap is a common way to generate results that cannot be attributed cleanly.

Why Cell-Culture Findings Do Not Transfer

The gap between a culture dish and an organism is unusually wide for this particular compound, and the reason is the same modification that makes it useful. In a dish there are no binding proteins worth speaking of, no hepatic clearance, no endocrine feedback from the growth hormone axis, and no competing tissue sinks. A protein engineered specifically to escape the binding proteins is therefore being evaluated in an environment that has already removed most of the regulation it was designed to bypass.

This is why observations of increased protein synthesis markers or proliferation in a myotube culture cannot be read as statements about tissue growth in an animal, let alone in a person. The measurement is real, the system is simplified by design, and the simplification is the point of the experiment. Researchers publishing in this area describe results in terms of receptor signaling and pathway activation rather than in terms of outcomes, and that restraint is a feature of the discipline rather than a hedge.

There is a second reason for caution specific to this compound. Growth factor signaling intersects with cell proliferation control, and the IGF-1 axis appears throughout the literature on proliferative biology for exactly that reason. That intersection makes the compound scientifically interesting and simultaneously makes casual extrapolation from a dish irresponsible. Nothing on this page describes an effect in a person, and any question about growth, muscle, metabolic, or proliferative health belongs with a licensed clinician.

Model Selection Follows the Question

Investigators studying receptor pharmacology tend to use cell lines with well-characterized receptor expression, since the goal is a clean dose-response relationship. Investigators studying differentiation use primary cultures or myoblast lines where the differentiation program can be tracked morphologically and transcriptionally. Investigators studying systemic regulation generally do not use this analog at all, because removing binding protein interaction removes the very layer they intend to measure. Matching the model to the question is the central design decision in this literature.

How IGF-1 LR3 Differs From Secretagogues in the Same Category

The growth hormone research category contains compounds that act at very different points in a signaling axis, and the difference is easy to lose when they are grouped by research area. Growth hormone releasing hormone analogs such as tesamorelin, and growth hormone secretagogues such as ipamorelin and CJC-1295, act upstream at the pituitary, where they are studied for their influence on the release of growth hormone itself. The axis then proceeds to the liver and peripheral tissues, where growth hormone signaling drives production of insulin-like growth factor 1.

IGF-1 LR3 sits at the far end of that chain. It is not studied for effects on release of anything. It is a direct receptor ligand, applied to a system that already expresses the receptor, and its endpoints are receptor-proximal. A researcher who wants to ask whether a pituitary cell model releases more growth hormone under a given condition needs a secretagogue. A researcher who wants to ask what the IGF-1 receptor does once it is engaged needs a receptor ligand. These are not interchangeable, and comparative context across the axis is available at the growth hormone secretagogues guide.

The distinction also changes what pulsatility means in an experiment. Secretagogue research frequently cares a great deal about the pulsatile pattern of release, because the physiological signal is pulsatile and a compound that flattens the pattern may produce different downstream biology than one that preserves it. Direct receptor stimulation in a dish has no pulsatile structure unless the experimenter imposes one, which is another way the simplified system diverges from intact physiology. Related questions are collected at growth hormone peptide questions.

Handling, Solubility, and Stability

IGF-1 LR3 is supplied as a lyophilized powder. It differs from most compounds in the research catalog in that it is a protein rather than a short synthetic peptide, produced by recombinant expression rather than by solid-phase synthesis, and it carries three disulfide bonds that hold a defined tertiary fold. That fold is not decorative. Receptor binding depends on it, and a preparation that has lost its structure can be chemically intact by mass while being biologically inert.

The practical consequence is that handling conditions matter more here than for a short linear peptide. Proteins of this class are sensitive to pH extremes, to elevated temperature, to vigorous agitation that can drive surface denaturation, and to repeated freeze-thaw cycling. Reconstitution solvent choice for this molecule is not the same question it is for a tripeptide, and mild acidic conditions are commonly used for the initial dissolution step in published protocols before dilution into a working buffer.

Aliquoting is close to mandatory rather than merely advisable. Because the vial size is typically small and the working concentrations are low, a single reconstituted vial often supports many experiments, and thawing it repeatedly is the most reliable way to lose activity without any visible sign that anything has changed. Concentration arithmetic should also be worked deliberately, since the molecular weight of an 83-residue protein sits far from the short peptides most researchers handle routinely. A calculator is available at reconstitution calculator.

• Supplied as lyophilized powder, produced recombinantly rather than by solid-phase synthesis.
• Structure includes three disulfide bonds, so biological activity depends on preserved folding, not mass alone.
• Sensitive to pH extremes, heat, vigorous agitation, and repeated freeze-thaw cycling.
• Aliquot after reconstitution; thawing a single vial repeatedly degrades activity without visible change.
• Molecular weight differs greatly from short synthetic peptides, so concentration arithmetic should be worked explicitly.

What Researchers Measure

Receptor-proximal endpoints come first. Phosphorylation of the IGF-1 receptor beta subunit, measured by immunoblot with phospho-specific antibodies, establishes that the receptor was engaged at all. Downstream phosphorylation of Akt and of ERK is then measured to characterize which cascade was activated and to what degree, and phosphorylation of ribosomal protein S6 or its kinase is commonly added as a readout further along the protein synthesis branch.

Functional endpoints depend on the cell system. In myoblast and myotube cultures, researchers track differentiation markers, myotube diameter, and protein synthesis rate measured by labeled amino acid incorporation. In proliferation-focused systems the endpoints are cell counts, incorporation assays marking DNA synthesis, and cell cycle distribution by flow cytometry. In survival-focused work the readouts are apoptosis markers such as caspase activation.

Control design deserves particular attention in this literature. Because the analog was engineered to reduce binding protein interaction, an experiment comparing it against native insulin-like growth factor 1 is comparing two variables at once unless binding protein content in the medium is characterized. Serum-containing media contain binding proteins; defined serum-free media may not. Reporting the medium composition is therefore not a formality but a condition for the result being interpretable by anyone else.

Why Purity and a Certificate of Analysis Matter

For a recombinant protein, purity means more than it does for a synthetic peptide, because there are more ways for a preparation to be wrong. Beyond ordinary chemical impurities, a recombinant preparation can carry host cell proteins, residual nucleic acid, endotoxin from the expression system, and, most consequentially, misfolded or aggregated forms of the target protein itself. Aggregates are especially troublesome because they can be present at meaningful levels while the mass spectrometry identity result looks entirely correct.

Endotoxin deserves specific mention. Bacterial endotoxin is a potent activator of inflammatory signaling in many cell types at very low concentrations, and if a preparation carries it, an experiment measuring inflammatory or stress-pathway readouts may be measuring the contaminant rather than the compound. This is a well-documented source of irreproducible results in cell biology generally, and it is a reason researchers working with recombinant material treat endotoxin content as an experimental parameter rather than an afterthought.

A Certificate of Analysis reports identity confirmation, typically by mass spectrometry, and purity, typically by high performance liquid chromatography, for the specific lot supplied. Lot specificity is the point, because a certificate describing a different batch says nothing about the vial in hand. Testing scope is described at Certificate of Analysis, guidance on reading the document is at purity testing and COA, and current specifications and stock are visible after creating a free research account at order.

Frequently asked questions

All guides · Order research peptides

External references: U.S. Food and Drug Administration · Peptide (Wikipedia)